Abbott Laboratories (NYSE:ABT) Shares Bought by Quilter Plc

Quilter Plc boosted its position in shares of Abbott Laboratories (NYSE:ABTGet Rating) by 20.7% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 6,281 shares of the healthcare product maker’s stock after acquiring an additional 1,076 shares during the quarter. Quilter Plc’s holdings in Abbott Laboratories were worth $744,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ABT. Bourgeon Capital Management LLC acquired a new stake in Abbott Laboratories during the 1st quarter worth about $30,000. Dravo Bay LLC purchased a new position in shares of Abbott Laboratories during the 1st quarter valued at about $32,000. Delos Wealth Advisors LLC raised its stake in shares of Abbott Laboratories by 100.9% during the 4th quarter. Delos Wealth Advisors LLC now owns 231 shares of the healthcare product maker’s stock valued at $33,000 after buying an additional 116 shares during the last quarter. Holloway Wealth Management LLC raised its stake in shares of Abbott Laboratories by 175.0% during the 1st quarter. Holloway Wealth Management LLC now owns 275 shares of the healthcare product maker’s stock valued at $33,000 after buying an additional 175 shares during the last quarter. Finally, Monumental Financial Group Inc. purchased a new position in shares of Abbott Laboratories during the 1st quarter valued at about $38,000. Institutional investors and hedge funds own 73.03% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on ABT shares. StockNews.com upgraded Abbott Laboratories from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, August 3rd. Wolfe Research started coverage on Abbott Laboratories in a research note on Tuesday, July 5th. They set an “underperform” rating for the company. Morgan Stanley reduced their price objective on Abbott Laboratories from $134.00 to $132.00 and set an “overweight” rating for the company in a research note on Thursday, July 21st. Citigroup cut their price target on Abbott Laboratories from $125.00 to $123.00 and set a “buy” rating for the company in a research note on Thursday, July 21st. Finally, Royal Bank of Canada cut their price objective on Abbott Laboratories from $143.00 to $132.00 in a research note on Thursday, July 21st. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $132.46.

Abbott Laboratories Trading Down 0.1 %

ABT opened at $105.78 on Thursday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.54 and a current ratio of 2.01. The business’s 50 day moving average price is $107.78 and its 200 day moving average price is $112.43. Abbott Laboratories has a one year low of $101.21 and a one year high of $142.60. The stock has a market capitalization of $185.24 billion, a PE ratio of 22.08, a P/E/G ratio of 4.02 and a beta of 0.72.

Abbott Laboratories (NYSE:ABTGet Rating) last released its quarterly earnings results on Wednesday, July 20th. The healthcare product maker reported $1.43 EPS for the quarter, topping analysts’ consensus estimates of $1.09 by $0.34. Abbott Laboratories had a return on equity of 29.38% and a net margin of 18.78%. The company had revenue of $11.26 billion for the quarter, compared to analysts’ expectations of $10.37 billion. During the same period in the prior year, the firm earned $1.17 earnings per share. The firm’s revenue was up 10.1% compared to the same quarter last year. As a group, equities research analysts expect that Abbott Laboratories will post 4.99 EPS for the current year.

Insider Transactions at Abbott Laboratories

In other news, CEO Robert B. Ford sold 102,425 shares of the company’s stock in a transaction on Thursday, August 25th. The stock was sold at an average price of $105.10, for a total transaction of $10,764,867.50. Following the sale, the chief executive officer now owns 142,071 shares of the company’s stock, valued at $14,931,662.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CEO Robert B. Ford sold 102,425 shares of the company’s stock in a transaction on Thursday, August 25th. The stock was sold at an average price of $105.10, for a total transaction of $10,764,867.50. Following the sale, the chief executive officer now owns 142,071 shares of the company’s stock, valued at $14,931,662.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Daniel J. Starks sold 50,000 shares of the company’s stock in a transaction on Tuesday, July 26th. The stock was sold at an average price of $109.14, for a total value of $5,457,000.00. Following the sale, the director now directly owns 6,923,500 shares in the company, valued at approximately $755,630,790. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 204,788 shares of company stock valued at $21,776,756. 0.52% of the stock is currently owned by company insiders.

About Abbott Laboratories

(Get Rating)

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Read More

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABTGet Rating).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.